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DISPOSABLE LIVES: 
COVID-19, VACCINES, AND THE UPRISING 
Matiangai Sirleaf* 
“If I can be provocative, shouldn’t this study be done in Africa, where there 
are no masks, no treatment, no intensive care, a bit like some studies on AIDS or 
among prostitutes. We try things, because we know they . . . are highly exposed and 
they don’t protect themselves. What do you think about that?” 
— Jean-Paul Mira, Head of the Intensive Care Unit at the Cochin 
Hospital in Paris, April 1, 20201 
 
“You’re right . . . . We’re currently thinking in parallel about a study in 
Africa with the same type of approach . . . . I think a call has been issued or will be 
issued and I think we are going to consider it.” 
— Camille Locht, Research Director at the French Institute of Health 
and Medical Research, Inserm, April 1, 20202 
INTRODUCTION 
Two French doctors appeared on television and publicly discussed po-
tentially utilizing African subjects in experimental trials for a tuberculosis 
vaccine as an antidote to the novel coronavirus (COVID-19).3 Tedros 
Adhanom Ghebreyesus, the Director-General of the World Health Organ-
ization (WHO), denounced these kinds of racist remarks as a “hangover 
from ‘colonial mentality’”4 and maintained that “Africa can’t and won’t be 
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 1. What French Doctors and the WHO Really Said About Africa and Vaccine Testing, 
Euronews, https://www.euronews.com/2020/04/07/what-french-doctors-and-the-who-really-
said-about-africa-and-vaccine-testing [https://perma.cc/ZFQ3-6H89] (last updated Aug. 4, 
2020). 
 2. Id. 
 3. James Ojo, Watch: Outrage as French Doctors Discuss Testing COVID-19 Vaccine 
in Africa, Cable Lifestyle (Apr. 2, 2020), https://lifestyle.thecable.ng/watch-outrage-as-
french-doctors-discuss-testing-covid-19-vaccine-in-africa [https://perma.cc/2J3K-5MSE]. 
 4. Coronavirus: Africa Will Not Be Testing Ground for Vaccine, Says WHO, BBC News 
(Apr. 6, 2020), https://www.bbc.com/news/world-africa-52192184 [https://perma.cc/
EYN8-UZEG]. 
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a testing ground for any vaccine.”5 The fallout on social media was simi-
larly swift, with Samuel Eto’o, a Cameroonian football legend, referring to 
the doctors as “[d]es assasins”6 and several others questioning the motives 
behind testing a vaccine on the African continent.7 The dialogue between 
the doctors and the strong reactions to their statements reopen the 
wounds of Black, Indigenous, and other people of color’s lives being 
treated as disposable. 
This Piece connects how racialized notions regarding which lives are 
disposable are reflected widely in the areas of health and human rights. 
The presumed expendability of Black lives is made manifest from systemic 
police violence, to the devastating racially disproportionate impact of 
COVID-19,8 to historic and ongoing medical experimentation, and to 
inequitable vaccine access.9 The twin pandemics of systemic racism and 
COVID-19 have heightened the visibility of the disposability with which 
society views the lives of people of color. The cumulative effect of this 
disposability furthers the devaluation of subordinated groups. Through 
exploring the theme of disposability, this Piece clarifies the roles of 
international human rights law, global public health, and international 
intellectual property law in either advancing racial justice efforts or 
contributing toward racial subordination. This period of racial reckoning 
and reform creates an opening to challenge the racial status quo in these 
areas and beyond. 
I. DISPOSABLE LIVES AND THE UPRISING 
The ongoing uprising challenges the assumption of disposability of 
Black lives in the United States and elsewhere. The seemingly unrelenting 
                                                                                                                           
 5. Id. 
 6. Samuel Eto’o (@SamuelEtoo), Twitter (Apr. 2, 2020), https://twitter.com/
SamuelEtoo/status/1245655021162659841?lang=en (on file with the Columbia Law Review). 
 7. See, e.g., Musa Okwonga, The French Doctors Who Wanted to Test Vaccines on 
Africans and Western Medicine’s Dark History, Quartz Afr. (Apr. 10, 2020), 
https://qz.com/africa/1836272/french-doctors-say-test-covid-19-vaccine-on-africans-spark-
fury (on file with the Columbia Law Review); Rim-Sarah Alouane (@RimSarah), Twitter (Apr. 
2, 2020), https://twitter.com/RimSarah/status/1245680422614446081 (on file with the 
Columbia Law Review). 
 8. Jazmyn T. Moore, Jessica N. Ricaldi, Charles E. Rose, Jennifer Fuld, Monica Parise, 
Gloria J. Kang, Anne K. Driscoll, Tina Norris, Nana Wilson, Gabriel Rainisch, Eduardo 
Valverde, Vladislav Beresovsky, Christine Agnew Brune, Nadia L. Oussayef, Dale A. Rose, 
Laura E. Adams, Sindoos Awel, Julie Villanueva, Dana Meaney-Delman & Margaret A. 
Honein, Disparities in Incidence of COVID-19 Among Underrepresented Racial/Ethnic 
Groups in Counties Identified as Hotspots During June 5–18, 2020—22 States, February–
June 2020, 69 Morbidity & Mortality Wkly. Rep. 1122, 1123 (2020) (“A high percentage of 
cases in hotspot counties are among persons of color.”). 
 9. Uché Blackstock & Oni Blackstock, Opinion, White Americans Are Being 
Vaccinated at Higher Rates than Black Americans. Such Inequity Cannot Stand., Wash. Post 
(Feb. 1, 2021), https://www.washingtonpost.com/opinions/2021/02/01/racial-inequality-
covid-vaccine (on file with the Columbia Law Review). 
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onslaught of police violence against Black people in the United States has 
resulted in many lives lost, both seen and unseen. Notoriously, Derek 
Chauvin, a Minneapolis police officer, kneed George Floyd to death for 
over nine minutes.10 During this time, George Floyd told officers, “I can’t 
breathe” more than twenty times while the officer’s knee remained on his 
neck.11 The officers treated him as disposable. In Louisville, several police 
officers shot and killed Breonna Taylor, an EMT worker who was sleeping 
when the police forcibly entered her home attempting to enforce a no-
knock warrant.12 Additionally, a former police officer killed Ahmaud 
Arbery for “jogging while Black” in Brunswick, Georgia.13 The banal 
circumstances surrounding their deaths indicate the precariousness of 
Black lives and the ease with which our lives can be disposed. The public 
health community has belatedly recognized that addressing police 
violence is a public health issue.14 
Mr. Floyd’s death vividly illustrates the relationship between police 
brutality, systemic racism, and health equity. The Hennepin County 
Medical Examiner’s autopsy report indicates that he was positive for 
COVID-19 at the time of his death.15 It also observes that he was likely 
asymptomatic with persistent positivity from a previous infection.16 Mr. 
Floyd’s positive test for COVID-19 on April 3, 2020 occurred nearly eight 
                                                                                                                           
 10. Nicholas Bogel-Burroughs, Prosecutors Say Derek Chauvin Knelt on George Floyd 
for 9 Minutes 29 Seconds, Longer than Initially Reported., N.Y. Times (Mar. 30, 2021), 
https://www.nytimes.com/2021/03/30/us/derek-chauvin-george-floyd-kneel-9-minutes-
29-seconds.html (on file with the Columbia Law Review). 
 11. Maanvi Singh, George Floyd Told Officers ‘I Can’t Breathe’ More than 20 Times, 
Transcripts Show, Guardian (July 9, 2020), https://www.theguardian.com/us-news/2020/
jul/08/george-floyd-police-killing-transcript-i-cant-breathe [https://perma.cc/HX4N-
UNZJ]. 
 12. Amina Elahi, ‘Sleeping While Black’: Louisville Police Kill Unarmed Black Woman, 
NPR (May 13, 2020), https://www.npr.org/2020/05/13/855705278/sleeping-while-black-
louisville-police-kill-unarmed-black-woman [https://perma.cc/35EE-GNLC]. 
 13. Zack Beauchamp, Ahmaud Arbery and the Dangers of Running While Black, Vox 
(May 8, 2020), https://www.vox.com/policy-and-politics/2020/5/8/21250914/ahmaud-
arbery-mcmichael-arrest-black-men-exercise (on file with the Columbia Law Review); see also 
Marie Andrusewicz, Georgia Attorney General Asks for DOJ Probe into Handling of 
Ahmaud Arbery Case, NPR (May 10, 2020), https://www.npr.org/2020/05/10/
853581211/georgia-attorney-general-asks-for-doj-probe-into-handling-of-ahmaud-arbery-
case [https://perma.cc/Q7A6-JYMW]. 
 14. See, e.g., Addressing Law Enforcement Violence as a Public Health Issue, Am. Pub. 
Health Ass’n (Nov. 13, 2018), https://www.apha.org/policies-and-advocacy/public-health-
policy-statements/policy-database/2019/01/29/law-enforcement-violence 
[https://perma.cc/LQ52-FWKM]; see also Sirry Alang, Donna McAlpine, Ellen McCreedy 
& Rachel Hardeman, Police Brutality and Black Health: Setting the Agenda for Public 
Health Scholars, 107 Am. J. Pub. Health 662, 662 (2017). 
 15. Andrew M. Baker, Hennepin County Medical Examiner’s Office Autopsy Report 3 
(June 1, 2020), https://www.hennepin.us/-/media/hennepinus/residents/public-safety/
documents/floyd-autopsy-6-3-20.pdf [https://perma.cc/Z6RG-Z3J7]. 
 16. Id. 
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weeks prior to when police murdered him.17 The Hennepin County 
autopsy report found that Mr. Floyd went into cardiopulmonary arrest 
while the police restrained him and that the police compressed his neck.18 
An independent autopsy report commissioned by the Floyd family found 
that his death was due to “asphyxiation from sustained pressure” when 
Minneapolis police officers compressed his neck and his back.19 It is telling 
that structural racism manifested in such a way that over Mr. Floyd’s brief 
life, he was more likely to encounter things that we know jeopardize life 
and limb—like systemic police violence and the racialized health inequi-
ties witnessed with COVID-19.20 
The ongoing racial reckoning inspired in part by Mr. Floyd’s death 
challenges the disposable nature with which his life and those of countless 
others are regarded. During the uprising, people across the globe joined 
together demanding full equality, accountability, and an end to police bru-
tality and systemic racial injustice.21 In the United States, the response to 
the Black Lives Matter uprising and allies protesting racial subordination 
included substantial militarization with armored vehicles, curfews, tear 
gas, pepper spray, and rubber and wooden bullets.22 The ongoing racial 
reckoning has illuminated how quickly and swiftly some states are willing 
to deploy the military and the police to quell those agitating for racial 
justice. This must be read against the drastically different state responses 
to the anti-lockdown protests occurring across the United States during 
the COVID-19 pandemic, which are characterized by the police showing 
                                                                                                                           
 17. Id. 
 18. Id. at 1. 
 19. Scott Neuman, Medical Examiner’s Autopsy Reveals George Floyd Had Positive 
Test for Coronavirus, NPR (June 4, 2020), https://www.npr.org/sections/live-updates-
protests-for-racial-justice/2020/06/04/869278494/medical-examiners-autopsy-reveals-
george-floyd-had-positive-test-for-coronavirus [https://perma.cc/6CGE-7STC]. 
 20. Ruqaiijah Yearby, Structural Racism: The Root Cause of the Social Determinants 
of Health, Petrie Flom Ctr.: Bill of Health (Sept. 22, 2020), https://blog.petrieflom.law.
harvard.edu/2020/09/22/structural-racism-social-determinant-of-health [https://perma.cc/
EGD2-LGW7]. 
 21. Damien Cave, Livia Albeck-Ripka & Iliana Magra, Huge Crowds Around the Globe 
March in Solidarity Against Policy Brutality, N.Y. Times (June 6, 2020), 
https://www.nytimes.com/2020/06/06/world/george-floyd-global-protests.html (on file 
with the Columbia Law Review) (last updated June 9, 2020). 
 22. Tom Nolan, Militarization Has Fostered a Policing Culture that Sets Up Protesters 
as ‘The Enemy’, Rice: Kinder Inst. for Urb. Rsch. (June 10, 2020), https://kinder.rice.edu/
urbanedge/2020/06/10/police-brutality-militarization-racism-protests 
[https://perma.cc/94RC-SF52]; Liz Szabo, Jay Hancock, Kevin McCoy, Donovan Slack & 
Dennis Wagner, Fractured Skulls, Lost Eyes: Police Break Their Own Rules when Shooting 
Protesters with ‘Rubber Bullets’, USA Today (June 19, 2020), https://www.usatoday.com/
in-depth/news/nation/2020/06/19/police-break-rules-shooting-protesters-rubber-bullets-
less-lethal-projectiles/3211421001 [https://perma.cc/5WJC-GAFE] (last updated Sept. 11, 
2020). 
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phenomenal restraint.23 Juxtaposing the two shows starkly how efforts to 
enforce the racial status quo and those that challenge racial hierarchy are 
regarded. The knowledge that those most detrimentally impacted by 
COVID-19 belong to different racial groups than the majority White24 anti-
lockdown protestors informed the grievance and entitlement of those 
seeking the premature lifting of COVID-19 restrictions. The implicit 
question was: Since the suffering and disposability associated with racial 
health inequities has historically been normalized, why should COVID-19 
be treated any differently and require more mutual regard and concern 
for subordinated groups? 
II. DISPOSABLE LIVES AND RACIAL HEALTH DISPARITIES 
The failure to protect historically subordinated groups has meant that 
Black people in the United States are dying at approximately 1.5 times the 
rate of White people from COVID-19.25 Additionally, Black lives lost 
account for nearly 20% of the deaths across the United States where race 
is known.26 Significantly, the glaring racial health disparities observed with 
                                                                                                                           
 23. Aymann Ismail, The Anti-Lockdown Protests Prove Police Know How to Treat 
Protesters Fairly, Slate (May 28, 2020), https://slate.com/news-and-politics/2020/05/police-
response-george-floyd-minneapolis-shutdowns.html [https://perma.cc/DL3C-NG6A]. 
 24. The author capitalizes the “W” in White in this Piece, contrary to the typical 
practice of the Columbia Law Review, to render Whiteness visible and avoid unparallel terms. 
The capitalization of White does not imply the existence of a single ethnic group. See Ann 
Thúy Nguyễn & Maya Pendleton, Recognizing Race in Language: Why We Capitalize 
“Black” and “White”, Ctr. for the Study of Soc. Pol’y (Mar. 23, 2020), https://cssp.org/
2020/03/recognizing-race-in-language-why-we-capitalize-black-and-white [https://perma.cc/
AP5K-PDAR] (“To not name ‘White’ as a race is, in fact, an anti-Black act which frames 
Whiteness as both neutral and the standard.”); see also Kwame Anthony Appiah, The Case 
for Capitalizing the B in Black, Atlantic (June 18, 2020), https://www.theatlantic.com/
ideas/archive/2020/06/time-to-capitalize-blackand-white/613159 (on file with the 
Columbia Law Review) (“Racial identities were not discovered but created . . . and we must 
all take responsibility for them. Don’t let them disguise themselves as common nouns and 
adjectives. Call them out by their names.”); Nell Irvin Painter, Opinion, Why ‘White’ Should 
Be Capitalized, Too, Wash. Post (July 22, 2020), https://www.washingtonpost.com/
opinions/2020/07/22/why-white-should-be-capitalized (on file with the Columbia Law 
Review) (“[W]hite Americans have had the choice of being something vague, something 
unraced and separate from race. A capitalized ‘White’ challenges that freedom, by 
unmasking ‘Whiteness’ as an American racial identity as historically important as 
“Blackness”—which it certainly is.”); Eve L. Ewing, I’m a Black Scholar Who Studies Race. 
Here’s Why I Capitalize ‘White.’, Medium (July 2, 2020), https://zora.medium.com/im-a-
black-scholar-who-studies-race-here-s-why-i-capitalize-white-f94883aa2dd3 [https://perma.cc/
89EP-39J2] (“Whiteness is . . . a specific social category that confers identifiable and 
measurable social benefits.”); Kanya Stewart, NABJ Statement on Capitalizing Black and 
Other Racial Identifiers, Nat’l Ass’n of Black Journalists (June 11, 2020), 
https://www.nabj.org/news/news.asp?id=512370 (on file with the Columbia Law Review). 
 25. The COVID Racial Data Tracker, COVID Tracking Project at The Atlantic, 
https://covidtracking.com/race [https://perma.cc/J43D-D4E9] (last visited Feb. 16, 
2021). 
 26. Jeremy A.W. Gold, Lauren M. Rossen, Farida B. Ahmad, Paul Sutton, Zeyu Li, 
Phillip P. Salvatore, Jayme P. Coyle, Jennifer DeCuir, Brittney N. Baack, Tonji M. Durant, 
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COVID-19 are not the result of innate susceptibility in historically 
subordinated groups.27 Accordingly, focusing on preexisting health 
conditions like hypertension, diabetes, obesity, and the higher prevalence 
of cardiovascular disease among Black people—which can make for 
greater and more severe and deadly complications with COVID-1928—
provides an incomplete picture. Instead, structural factors that ensure that 
Black people are “more likely to encounter those things that we know 
compromise health—like inaccessible or biased health care providers, 
inadequate schools and education systems, unemployment, hazardous 
jobs, unsafe housing, and violent, polluted communities”29—provide a 
more robust explanation for the racial disparities witnessed with COVID-
19. For instance, those with higher incomes are better able to follow social 
distancing guidelines, while lower-income individuals are not,30 and 
people of color are overrepresented among “essential workers.”31 For 
example, Black workers are about one in nine workers overall in the 
United States, yet they make up about one in six of all front-line-industry 
workers.32 Essential personnel employed in transportation, sanitation, 
retail, and other public-facing sectors tend to face greater risks from 
COVID-19 because such jobs require greater contact with the public and 
have minimal structural protections like paid sick days and adequate 
                                                                                                                           
Kenneth L. Dominguez, S. Jane Henley, Francis B. Annor, Jennifer Fuld, Deborah L. Dee, 
Achuyt Bhattarai & Brendan R. Jackson, Race, Ethnicity, and Age Trends in Persons Who 
Died from COVID-19—United States, May–August 2020, 69 Morbidity & Mortality Wkly 
Rep. 1517, 1518 (2020). 
 27. Khiara M. Bridges, The Many Ways Institutional Racism Kills Black People, Time 
(June 11, 2020), https://time.com/5851864/institutional-racism-america [https://perma.cc/
2UF5-BDSN]; see also Ladan Golestaneh, Joel Neugarten, Molly Fisher, Henny H. Billett, 
Morayma Reyes Gil, Tanya Johns, Milagros Yunes, Michele H. Mokrzycki, Maria Coco, Keith 
C. Norris, Hector R. Perez, Shani Scott, Ryung S. Kim & Eran Bellin, The Association of 
Race and COVID-19 Mortality, 25 EClinicalMedicine 1, 6 (2020) (“Black patients engaged 
in care did suffer disproportionate higher mortality in the COVID period . . . .”). 
 28. See, e.g., Kristen M.J. Azar, Zijun Shen, Robert J. Romanelli, Stephen H. Lockhart, 
Kelly Smits, Sarah Robinson, Stephanie Brown & Alice R. Pressman, Disparities in Outcomes 
Among COVID-19 Patients in a Large Health Care System in California, 39 Health Affs. 
1253, 1260–61 (2020); Manish Pareek, Mansoor N. Bangash, Nilesh Pareek, Daniel Pan, 
Shirley Sze, Jatinder S. Minhas, Wasim Hanif & Kamlesh Khunti, Ethnicity and COVID-19: 
An Urgent Public Health Research Priority, 395 Lancet 1421, 1421–22 (2020). 
 29. Bridges, supra note 27. 
 30. Nicholas W. Papageorge, Matthew V. Zahn, Michèle Belot, Eline van den Broek-
Altenburg, Syngjoo Choi, Julian C. Jamison & Egon Tripodi, Socio-Demographic Factors 
Associated with Self-Protecting Behavior During the COVID-19 Pandemic, 34 J. Population 
Econ. 691, 693–94 (2021). 
 31. Dion Rabouin, Black Workers Overrepresented in Essential Work During 
Coronavirus Pandemic, Axios (June 3, 2020), https://www.axios.com/black-workers-
essential-coronavirus-c502fc2e-a4fc-4c4f-ae0c-722a50d74ecd.html [https://perma.cc/7BKA-
ZPQU]. 
 32. Elise Gould & Valerie Wilson, Econ. Pol’y Inst., Black Workers Face Two of the 
Most Lethal Preexisting Conditions for Coronavirus—Racism and Economic Inequality 4 
(2020), https://files.epi.org/pdf/193246.pdf [https://perma.cc/LTZ2-H2N2]. 
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health insurance.33 The racialized health disparities of the COVID-19 
pandemic have vividly exposed systemic racism and clarified which 
communities are deemed disposable. 
The COVID-19 pandemic implicates several fundamental human 
rights, including protections against the arbitrary deprivation of life and 
the “right of everyone to the enjoyment of the highest attainable standard 
of physical and mental health.”34 Under the International Covenant on 
Economic, Social and Cultural Rights (ICESCR), affected states are to take 
primary responsibility to prevent, treat, and control diseases.35 Addition-
ally, a fundamental principle of economic, social, and cultural rights is that 
a state should “take steps . . . to the maximum of its available resources, 
with a view to achieving progressively” the right to health as well as other 
economic, social, and cultural rights.36 Notably, only state parties to the 
Covenant on Economic, Social and Cultural Rights are accountable for 
compliance with it.37 Moreover, under the ICESCR, state parties 
“undertake to prohibit and to eliminate racial discrimination in all its 
forms and to guarantee the right of everyone, without distinction as to 
race, color, or national or ethnic origin, to equality before the law” in the 
right to public health, amongst others.38 
Further, the International Covenant on the Elimination of All Forms 
of Racial Discrimination (CERD) regime broadly defines racial discrimi-
nation to encompass any “distinction, exclusion, restriction or preference 
based on race, color, descent, or national or ethnic origin which has the 
purpose or effect of nullifying or impairing the recognition, enjoyment or 
                                                                                                                           
 33. Celine McNicholas & Margaret Poydock, Who Are Essential Workers? A 
Comprehensive Look at Their Wages, Demographics, and Unionization Rates, Econ. Pol’y 
Inst.: Working Econ. Blog. (May 19, 2020), https://www.epi.org/blog/who-are-essential-
workers-a-comprehensive-look-at-their-wages-demographics-and-unionization-rates 
[https://perma.cc/3MSW-4A3G]. 
 34. See International Covenant on Civil and Political Rights art. 6(1), Dec. 16, 1996, 
999 U.N.T.S. 171 (“Every human being has the inherent right to life.”); International 
Covenant on Economic, Social and Cultural Rights art. 12(1), Dec. 16, 1966, 993 U.N.T.S. 
3 [hereinafter ICESCR]. 
 35. ICESCR, supra note 34, art. 12(2)(c). 
 36. Id. art. 2. 
 37. See, e.g., id. (requiring state parties to take steps to realize the rights recognized in 
the Covenant). Some countries have not recognized socioeconomic rights as legally binding 
primary obligations. See International Covenant on Economic, Social and Cultural Rights, 
UN Treaty Collection, https://treaties.un.org/doc/Publication/MTDSG/Volume%20I/
Chapter%20IV/IV-3.en.pdf (on file with the Columbia Law Review) (last visited Sept. 28, 
2019) (noting that the Covenant has 171 state parties). Notably, the United States, Palau, 
the Comoros, and Cuba have not ratified the treaty. Id. 
 38. International Convention on the Elimination of All Forms of Racial Discrimination 
art. 5, Dec. 21, 1965, 660 U.N.T.S. 195 [hereinafter CERD]; see also ICESCR, supra note 34, 
art. 2(2) (“States Parties to the present Covenant undertake to guarantee that the rights 
enunciated in the present Covenant will be exercised without discrimination of any kind as 
to race, colour, sex, language, religion, political or other opinion, national or social origin, 
property, birth or other status.”). 
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exercise . . . of human rights and fundamental freedoms in the political, 
economic, social, cultural or any other field of public life.”39 International 
human rights law explicitly allows claims based on disparate impact by 
allowing discrimination claims based on effect.40 Significantly, the CERD 
framework for combatting discrimination is more expansive than the 
United States’ equal protection jurisprudence, which primarily focuses on 
purposive discrimination. Moreover, the availability of disparate impact 
claims in the United States has been severely hampered due to require-
ments that claims reach a certain threshold level of significance and 
demonstrate a causal relationship, and by the business necessity defense.41 
Internationally, disparate impact claims have not been hollowed out to the 
same extent, which is welcome news for those hoping to challenge racial-
ized global health inequities seen with COVID-19. 
CERD potentially creates an avenue for destabilizing racialized health 
inequities, because under the Convention, state parties are supposed to 
“take effective measures to review governmental, national and local poli-
cies, and to amend, rescind or nullify any laws and regulations which have 
the effect of creating or perpetuating racial discrimination wherever it 
exists.”42 The CERD regime is potentially very useful for addressing 
racialized health inequities because its applicability goes beyond laws and 
policies that are invidious by design. By focusing on the impact and effects 
of laws, policies, and actions, the CERD regime supplies fertile ground for 
generating creative challenges to racialized health inequities observed 
with COVID-19. 
While the CERD framework is laudable in significant ways, it faces 
several obstacles in effectively combatting racialized health inequities. For 
example, Article 2 of the Convention provides:  
State Parties shall, when the circumstances so warrant, [to 
account for] the social, economic, cultural and other fields, 
special and concrete measures to ensure the adequate 
development and protection of certain racial groups or 
individuals belonging to them, for the purpose of guaranteeing 
them the full and equal enjoyment of human rights and 
fundamental freedoms.43 
CERD’s state-centric framework prioritizes “groups or individuals 
belonging” to states and may fundamentally curtail the ability to raise 
transnational or global racial justice claims.44 Further, the Convention en-
visions the creation of limited state-based programs when both global and 
                                                                                                                           
 39. CERD, supra note 38, art. 1 (emphasis added). 
 40. Comm. on the Elimination of Racial Discrimination, Rep. of the Comm. on the 
Elimination of Racial Discrimination, U.N. Doc. A/48/18, at 115 (Sept. 15, 1993). 
 41. Mary Crossley, Disparate Impact in Law and Bioethics 9 (Sept. 27, 2019) (on file 
with the Columbia Law Review). 
 42. CERD, supra note 39, art. 2(1)(c). 
 43. Id. art. 2. 
 44. Id. art. 1(4). 
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state interventions are necessary to remedy global health inequities wit-
nessed with COVID-19. Additionally, the Convention cautions that any 
affirmative action measures “shall in no case entail as a consequence the 
maintenance of unequal or separate rights for different racial groups after 
the objectives for which they were taken have been achieved.”45 This 
temporal limitation could be read narrowly in ways that inhibit the ability 
to address the continued effects of racial subordination in health that 
inform the trajectory of the COVID-19 pandemic. Alternatively, this 
provision could theoretically apply until state actors achieve substantive 
equality in health. 
Overall, the CERD regime potentially creates a useful platform for 
legal and institutional reform. Ultimately, addressing the impact of racial 
inequities in global health exhibited during the COVID-19 pandemic 
requires significant legal and institutional restructuring to shift how 
people, society, and laws respond to diseases depending on which racial 
populations are deemed disposable.46 
III. DISPOSABLE LIVES AND EXPERIMENTAL TRIALS 
The discussion between the doctors in the Introduction reveals the 
way that disposability and medical neocolonialism are intertwined and 
reflexively invoked.47 The concept of medical neocolonialism aptly 
characterizes the pattern of extraction of resources from Black and other 
people of color for experimental clinical trials.48 The knowledge gener-
ated from this research is subsequently utilized for the development of new 
treatments and drugs. However, the subjects of the research and their 
communities generally do not share equitably in the benefits of these 
innovations.49 Medical neocolonialism draws on many of the characteris-
tics of historical colonialism in that it is similarly driven by economic 
dependence, exploitation, inequality, and the treatment of communities 
of color as disposable. 
Given the stark racial disparities witnessed with COVID-19, there is 
understandable skepticism that COVID-19 vaccines will be used to help 
subordinated groups, since we have generally not been protected in the 
first place. An Associated Press nationwide poll conducted between May 
14–18, 2020 (approximately a week before the police killed Mr. Floyd), 
revealed that, while 56% of White people were willing to take a potential 
COVID-19 vaccine, only 37% of Latinx and 25% of Black people would do 
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the same.50 The following month, the University of Oxford announced it 
would begin a new trial of its COVID-19 vaccine in Johannesburg, South 
Africa.51 In June 2020, protestors challenged the trials as exploiting 
African people as “guinea pigs,” informed by the ongoing disposability 
with which their lives are regarded.52 
In response, some have stressed the necessity of diversity in clinical 
trials in ways that problematically reify biological understandings of race.53 
Others have dismissed concerns about the vaccine as irrational in the face 
of a public health emergency.54 Yet, the resistance of Black people from 
the United States to South Africa must be contextualized against both 
present and past experiences with systemic racism. Indeed, the sordid 
history of human experimentation carried out on Black and other people 
of color has reinforced the disposable nature with which our lives are 
regarded: from J. Marion Sims conducting unanesthetized fistula surgeries 
on enslaved Black women’s bodies based on the stereotyped belief that 
Black people have a high tolerance for pain;55 to the notorious Tuskegee 
syphilis experiments, wherein health authorities deliberately failed to treat 
and misled 600 Black men about the nature of their care;56 to the 
exploitation of Henrietta Lacks in research;57 and to present day issues 
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with clinical trials that treat Black and other people of color as 
disposable.58 
This past is very much present, and unethical trials on Black and other 
people of color continue to take place on the African continent and else-
where. For example, in 1996, during the worst ever meningitis outbreak 
on the African continent, Pfizer conducted a clinical trial in which a 
hundred children in Nigeria were given an experimental oral antibiotic 
called Trovan, while an additional hundred received Ceftriaxone.59 Five 
children died on the former antibiotic and six on the latter.60 Some chil-
dren allegedly received a dose lower than recommended, “leaving many 
children with brain damage, paralysis, or slurred speech.”61 The parents of 
the children sued Pfizer for failure to obtain informed consent and Pfizer 
settled the suit with the drug trial victims after a protracted fifteen-year 
legal battle.62 
Moreover, early research trials conducted in Uganda for an AIDS 
vaccine were designed to test the safety of HIV Subtype B—a type most 
prevalent in Europe and the Americas.63 HIV has more than ten major 
subtypes, which correspond with geographical range;64 Subtype D is the 
dominant form in East Africa.65 Thus, the research done in Uganda tested 
a vaccine designed to attack a virus subtype not prevalent in Uganda.66 
Developers wanted a vaccine for Subtype B of HIV to market to high-
income countries in Europe and elsewhere in the Global North.67 
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Boehringer Ingelheim also supported suspect clinical trials in Uganda 
between 1997 and 2003 that led to thousands of serious adverse effects for 
women taking the anti-HIV transmission drug Nevirapine.68 Their 
symptoms went unreported, but testing continued and resulted in the 
deaths of fourteen of these women.69 
Furthermore, during the 2014–2016 Ebola outbreak, an Italian NGO 
tested the heart drug Amiodarone on Ebola patients at a treatment facility 
in Sierra Leone.70 The drug is not among the fifty-three drugs listed to 
have an antiviral effect on Ebola.71 Some British medics working at the 
center concluded that the side effects from the drug could be contributing 
to the increased morbidity within the center.72 Certain medical staff staged 
a walk-out from the facility to protest the use of the drug outside of a 
clinical trial concomitant with the lack of informed consent obtained from 
patients.73 Some researchers also took thousands of blood samples from 
Ebola patients during the 2014–2016 epidemic and now hold these 
samples in secretive laboratories around the world.74 Ebola survivors did 
not consent to their blood being used for research.75 Several African 
scientists accused the laboratories of “biological asset stripping,” as the 
scientists are unable to access the samples for their own research despite 
African health practitioners assuming all the risk in drawing the blood.76 
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These incidents are clear violations of established research guidelines, 
reflected in the World Medical Association’s Declaration of Helsinki and 
the WHO’s Handbook for Good Clinical Research Practice. Furthermore, 
they indicate the limitations of the guidelines’ ability to protect the rights 
and welfare of Black and other people of color.77 Moreover, even where 
legal and regulatory frameworks exist on paper for study participants, the 
de facto policy of treating Black, Indigenous, and other people of color as 
disposable requires more robust mechanisms to counteract the praxis of 
dehumanization. Accordingly, the unethical treatment and exploitation of 
subordinated groups informs the hesitancy of some to participate in 
clinical trials and to sign up for the COVID-19 vaccines authorized for 
emergency use. 
IV. DISPOSABLE LIVES AND ACCESS TO VACCINES 
Importantly, however, the turn to “vaccine hesitancy” to account for 
the gross disparities in the distribution of the COVID-19 vaccines obscures 
structural, legal, and policy barriers to access. For example, vaccine 
redlining policies have located many distribution centers outside of 
communities of color in the United States. Indeed, officials in Dallas 
County had to stop a plan prioritizing COVID-19 vaccine doses for people 
living in the most vulnerable zip codes after the state of Texas threatened 
to cut off the county’s vaccine supply.78 Moreover, preliminary data from 
states that track vaccination data by race indicate that COVID-19 vaccines 
are primarily going to White people, despite the fact that the pandemic is 
ravaging communities of color disproportionately.79 Commentators 
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developed the concept of vaccine apartheid to capture the nature of these 
stark inequities.80 
Vaccine apartheid is similarly glaring when examining access to 
vaccines internationally. Globally, vaccine redlining has meant that people 
living in many countries in the Global South are not expected to have 
significant doses of vaccines administered until as late as 2024.81 Some of 
this delay is the result of limited supply, lack of production facilities, and 
logistical impediments, such as the need for vaccine storage at subzero 
temperatures requiring the development of a cold distribution chain for 
vaccine administration.82 Moreover, international solidarity has been 
wanting; instead, vaccine nationalism has predominated, with some 
countries prioritizing and competing for bilateral deals and hoarding 
enough supplies to vaccinate their populations several times over.83 
Indeed, some analyses indicate that rich countries are on track to hoard 
over one billion COVID-19 vaccines.84 Further, the European Union 
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authorized its member states to put limitations on the exportation of 
vaccines.85 
Concomitantly, wealthy countries have failed to adequately support 
and fund global health schemes like COVAX,86 which is the main initiative 
of the WHO to provide COVID-19 vaccinations to people in low- and 
middle-income countries.87 COVAX requires financial contributions and 
donations from wealthy countries to work.88 Yet, it is unseemly and unjust 
for wealthy countries to hoard vaccines and drive up prices on the one 
hand, which makes it difficult for other countries to acquire vaccines, 
while also promising charitable donations that are insufficient. Further, 
even if the COVAX initiative were fully funded, a philanthropic model that 
relies on the munificence of others to donate money or share vaccine 
surpluses is fundamentally flawed, given the need for countries to 
vaccinate entire populations. In late February 2021, Ghana became the 
first country to receive vaccine doses under this scheme.89 Yet, the late 
“timing and the relatively modest supply—enough for just 1% of Ghana’s 
population—point to major challenges”90 moving forward. Indeed, by 
April 2021, COVAX “distributed 43 million doses of vaccine to 119 
countries—covering just 0.5 percent of their combined population of 
more than four billion.”91 Additionally, as detailed below, an artificially 
limited supply of vaccines is caused by Big Pharma’s monopoly on prices 
and profit, which exacerbates inequities and results in more restricted or 
delayed vaccine access for many countries in the Global South. Moreover, 
COVAX depends on extant power relations that are skewed in favor of the 
                                                                                                                           
 85. Obiora Chinedu Okafor & James Thuo Gathii, The EU’s Vaccine Export Controls 
Negate Its Self-Interest, International Solidarity and International Law, Afronomics L. (Feb. 
18, 2021), https://www.afronomicslaw.org/category/analysis/eus-vaccine-export-controls-
negate-its-self-interest-international-solidarity-and [https://perma.cc/5KNN-XGNB] (dis-
cussing the EU’s binding regulations that authorize member states “to limit the export of 
COVID-19 vaccines produced within its borders”). 
 86. See, e.g., Anna Rouw, Jennifer Kates, Josh Michaud & Adam Wexler, COVAX and 
the United States, Kaiser Fam. Found. (Feb. 18, 2021), https://www.kff.org/coronavirus-
covid-19/issue-brief/covax-and-the-united-states [https://perma.cc/6ZMS-R2FA] (discussing 
funding and regulatory challenges with COVAX). 
 87. COVAX: Working for Global Equitable Access to COVID-19 Vaccines, WHO, 
https://www.who.int/initiatives/act-accelerator/covax [https://perma.cc/C9V7-2CBX] (last 
visited Feb. 13, 2021). 
 88. Rouw et al., supra note 86 (“COVAX has an overall funding target (2020–2021) of 
$11.1 billion but faces a $7.2 billion funding gap. Given the economic crisis that has gripped 
much of the world due to COVID-19, it is not yet clear how this gap can be filled.”). 
 89. Danielle Paquette & Emily Rauhala, First Vaccine Doses Distributed by Covax Land in 
West African Nation of Ghana, Wash. Post. (Feb. 24, 2021), https://www.washingtonpost.com/
world/africa/covax-ghana-astrazeneca-vaccine/2021/02/24/558d31bc-7617-11eb-9489-
8f7dacd51e75_story.html (on file with the Columbia Law Review). 
 90. Id. 
 91. Tedros Adhanom Ghebreyesus, Opinion, I Run the W.H.O., and I Know that Rich 
Countries Must Make a Choice, N.Y. Times (Apr. 22, 2021), https://www.nytimes.com/
2021/04/22/opinion/who-covid-vaccines.html (on file with the Columbia Law Review). 
86 COLUMBIA LAW REVIEW FORUM [Vol. 121:5 
pharmaceutical industry and countries where the production of vaccine 
doses takes place. 
South Africa is a prime case study of vaccine apartheid, as it is one of 
the first countries on the African continent to procure a vaccine and is also 
one of the hardest hit by the pandemic.92 Notably, the Oxford–
AstraZeneca vaccine, the trials for which were greeted with protests in 
Johannesburg,93 has an increasingly uncertain future in South Africa and 
beyond.94 The Oxford–AstraZeneca vaccine was supposed to be used 
widely in countries in the Global South, as the manufacturer projected 
that it could quickly produce billions of doses.95 This supply is substantially 
greater and at a significantly lower price than any of the other vaccines 
shown to offer protection against COVID-19.96 
Recalling the concept of medical neocolonialism is instructive here, 
as South Africa obtained millions of vaccine doses at a cost of $5.25 per 
dose, which is more than double the $2.16 per dose that European Union 
countries paid to AstraZeneca.97 Moreover, since South Africans initially 
participated in clinical trials for the development of the drug, they should 
have had greater post-trial access and benefit-sharing based on fundamen-
tal principles of research referenced earlier.98 Instead, South Africa had to 
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pay more for a drug it ultimately will not be able to use. The trial of the 
vaccine revealed comparatively low efficacy rates (under 25%) against mild 
and moderate cases of the disease in South Africa, a threshold that does 
not “meet minimal international standards for emergency use.”99 South 
Africa has discontinued its plans to use the AstraZeneca vaccine, given the 
vaccine’s ineffectualness against a newer variant of the virus that is preva-
lent in South Africa.100 At the time of writing, its national immunization 
drive is in flux. This is compounded by Moderna’s (manufacturer of one 
of the most expensive COVID-19 vaccines101) earlier indication that it did 
not plan to distribute its vaccine in South Africa.102 Significantly, a single 
dose of the Moderna vaccine costs approximately $32–$37 and has an 
efficacy of approximately 95%.103 While Moderna pledged not to enforce 
its patent during the COVID-19 pandemic,104 it does not own all the 
patents in its vaccine.105 Accordingly, Moderna cannot make credible 
commitments that bind other patentholders. 
Conventional analyses would simply treat vaccine apartheid as driven 
by and fully accounted for by poverty. Such shallow analyses, however, tend 
to obscure the functioning of race and histories of subordination, which is 
why the concept of medical neocolonialism is so useful. The South African 
example vividly illustrates how “the fruits of medical and scientific 
advances are stockpiled for some and denied for others.”106 By failing to 
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take an intersectional approach, traditional analyses may not fully capture 
how multiple overlapping areas such as race, class, and geography may 
function to produce heightened subordination. The political economy 
explanation also does not consider how market failures for 
pharmaceuticals aimed at diseases that disproportionately impact people 
of color are tied to long histories of exploitation, dispossession, and 
devaluation of the lives of Black, Indigenous, and other people of color. 
A thorough analysis of COVID-19 vaccine apartheid and disposability 
must also consider the role of the international intellectual property 
regime in severely compounding the challenges of equitable vaccine 
distribution. Briefly, the international intellectual property regime 
provides a twenty-year monopoly for pharmaceuticals.107 Until the creation 
of this regime, many countries did not even place patent protection on 
pharmaceuticals. Previously, states regarded patent rights as a national 
prerogative rather than a minimum international substantive regime with 
standards for what intellectual property rights protections countries 
should adopt. Recognizing this, the Trade-Related Aspects of Intellectual 
Property Rights (TRIPS) Agreement grants extra implementation time to 
developing countries and delayed implementation for the least-developed 
countries.108 
Although the DOHA Declaration, which reaffirms the TRIPS 
Agreement, and some TRIPS provisions were meant to create better flexi-
bilities for public health or incentivize research and development, they 
have had limited effect in facilitating access to medicines,109 given the 
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larger incentive structure toward profit maximization.110 Indeed, the 
creation of the international intellectual property regime and the 
ratification of this regime in the Doha Declaration has functioned to 
expand and increase U.S.-style pharmaceutical patent protection 
globally.111 Further, the United States often threatens to close off its 
market to countries that run afoul of its interpretation of what the TRIPS 
regime requires for protecting pharmaceuticals.112 The United States and 
others also advance their structural power against states in the Global 
South through a mix of TRIPS-plus provisions placed in bilateral and 
regional free-trade agreements that have imposed much more stringent 
requirements on countries than required by TRIPS.113 
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Conventional wisdom holds that pharmaceutical companies depend 
on charging monopoly prices to recover their investments in experimental 
drugs and technologies.114 Yet, there are well-established arguments that a 
market-based monopoly incentive for pharmaceuticals is ill-suited for 
addressing health needs.115 Commentators have artfully pointed out the 
severe limitations of a research and innovation system based on monopoly 
rights.116 Such a system tends to focus research and development efforts 
toward “lucrative” medical conditions that pose minimal risks and toward 
ailments that already have existing effective therapies.117 This incentive 
system allows many pharmaceutical corporations to benefit substantially 
from publicly funded research and still charge monopoly prices. Overall, 
the intellectual property regime shelters corporations from competition, 
enables them to increase prices, underproduces certain drugs, cuts back 
on product quality, and declines to produce some pharmaceuticals.118 
Vaccines in particular have been deprioritized by the pharmaceutical 
industry as insufficiently profitable. This was the case with the Ebola virus, 
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which first appeared in 1976.119 Until the West African Ebola outbreak in 
2014, no approved vaccine existed,120 resulting in fatal and devastating 
consequences for many.121 The swift development of the COVID-19 
vaccines was the result of work done in academic labs with public funding 
and benefitted from the significant financial investment by wealthy 
governments that negotiated massive buyout contracts relying on money 
from taxpayers.122 As discussed above, wealthier countries rushed to outbid 
each other to secure vaccines from a limited supply. Yet, there is an 
insufficient supply of vaccines in part because pharmaceutical companies 
exercise their monopoly power to prevent others from accessing the 
publicly funded technologies needed to create the vaccines. For example, 
in 2020, the WHO created a technology access pool to encourage 
pharmaceutical companies to share their knowledge with manufacturers 
in other countries that need to develop vaccines, but not one company has 
done so at the time of writing.123 
Against this background, in October 2020, India and South Africa 
requested that the Council for TRIPS recommend a waiver from the 
implementation, application, and enforcement of certain provisions of the 
TRIPS Agreement.124 They argued that a waiver was needed to prevent, 
contain, and treat COVID-19, given the acute health shortages faced by 
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many countries. India and South Africa requested that the “waiver should 
continue in effect until widespread vaccination is in place globally, and the 
majority of the world’s population has developed immunity.”125 Changing 
the incentive structures for the research and development of drugs, 
including suspending the application of trade-related intellectual property 
rights to essential drugs for lower-income countries, has been proposed 
before.126 Notably, the UN’s High-Level Panel on Access to Medicines has 
not gone as far, but its recommendations recognize the need to alter the 
legal environment such that international treaties improve, rather than 
hinder, access to innovation.127 
India and South Africa’s joint submission seeks to substantially 
reshape the TRIPS regime by allowing for deep technology transfer for 
effective COVID-19 vaccines, therapeutics, and diagnostic tests. The joint 
submission is wide-ranging and covers not only patents, but also copyright, 
industrial designs, and undisclosed information including know-how and 
trade secrets.128 The purpose of the temporary ban would be to allow mul-
tiple actors to start production, instead of limiting manufacturing to the 
small number of current patent-holders, which limits access and renders 
significant numbers of people disposable. The proposal has found support 
from the African group of countries and other developing countries at the 
World Trade Organization.129 In May 2021, the Biden Administration 
indicated that “[t]he US supports the waiver of IP protections on COVID-
19 vaccines to help end the pandemic and we’ll actively participate in . . . 
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negotiations [at the WTO] to make that happen.”130 The pharmaceutical 
industry and wealthy countries like the United Kingdom, those in the 
European Union, and others oppose the proposal to waive intellectual 
property rights.131 Significantly, the South African intervention before the 
TRIPS Council notes that the countries opposing the waiver proposal ac-
count for 60% of the globally administered COVID-19 vaccines.132 In their 
view, intellectual property rights are not a barrier to access, as the current 
system is required to incentivize new inventions. The opposing countries 
maintain that equitable access can be achieved through voluntary licens-
ing and technology transfer arrangements, among other means.133 Yet, this 
Piece has already illustrated the severe constraints of voluntary transfer 
arrangements,134 and as South Africa’s first intervention before the TRIPS 
Council aptly put it, “the problem with philanthropy is that it cannot buy 
equality.”135 Given the diametrically opposed positions on the proposal, 
reaching a consensus (which is the way most decisions are made) in the 
TRIPS Council is unlikely in the immediate future.136 
Accordingly, the goal of delivering “triple billion” COVID-19 vaccine 
doses to the world’s most vulnerable populations appears elusive given the 
current impasse.137 In January 2021, the Director-General of the WHO 
warned that the world is on the “brink of a catastrophic moral failure––
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and the price of this failure will be paid with lives and livelihoods in the 
world’s poorest countries.”138 If the current course is not corrected, 
vaccine apartheid will only deepen, and the resulting maldistribution will 
render historically subordinated groups even more disposable. That 
exacerbating racial subjugation was not the intention of law and 
policymakers in the intellectual property regime when structuring legal 
incentives for research and pharmaceutical innovation is immaterial. 
Indeed, this does not render the impact of further entrenching racial 
subordination any less acute. Nor does it alleviate the obligation of actors 
to remedy the inequitable racialized disparities with vaccine access that 
have resulted with COVID-19. 
CONCLUSION 
The twin pandemics of COVID-19 and systemic racism and the 
responses to halt their spread have fundamentally challenged the status 
quo. The uprising and its insistence on the value of Black lives creates an 
opening to rethink, reshape, and create new possibilities for antisubordi-
nation efforts. Yet, as this Piece shows, the presumption of the disposability 
of people of color implicitly persists in disparate areas of law and policy. 
This Piece highlights several areas for reformation and restructuring. Fur-
ther research should aim to reconcile the inconsistencies between the 
rights to health and equality provided by international human rights law 
on the one hand and trade-related intellectual property rights on the 
other. Additionally, addressing systemic police violence, racialized global 
health inequities, and medical experimentation and exploitation, as well 
as vaccine apartheid and redlining, will require a significant level of legal 
reform and restructuring to counteract years of entrenched racial subor-
dination. This Piece makes clear that changing the baseline of disposability 
is required to begin to shift how people, society, and laws respond to Black 
lives now and in the future. 
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